Middleton & Co. Inc. MA Has $2.09 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Middleton & Co. Inc. MA raised its position in Zoetis Inc. (NYSE:ZTS) by 30.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,062 shares of the company’s stock after buying an additional 2,811 shares during the quarter. Middleton & Co. Inc. MA’s holdings in Zoetis were worth $2,091,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Aveo Capital Partners LLC bought a new stake in Zoetis during the fourth quarter worth $225,000. Gryphon Financial Partners LLC raised its holdings in shares of Zoetis by 11.8% during the 4th quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock worth $601,000 after buying an additional 322 shares in the last quarter. Jump Financial LLC bought a new stake in shares of Zoetis during the 4th quarter worth $339,000. Level Four Advisory Services LLC boosted its stake in Zoetis by 11.7% in the fourth quarter. Level Four Advisory Services LLC now owns 1,504 shares of the company’s stock valued at $297,000 after buying an additional 157 shares in the last quarter. Finally, TrinityPoint Wealth LLC raised its stake in Zoetis by 0.3% during the fourth quarter. TrinityPoint Wealth LLC now owns 22,319 shares of the company’s stock worth $4,405,000 after acquiring an additional 73 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Up 0.4 %

Zoetis stock opened at $196.48 on Thursday. The firm has a market cap of $89.65 billion, a price-to-earnings ratio of 37.86, a PEG ratio of 2.98 and a beta of 0.88. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The firm has a 50 day moving average price of $184.11 and a two-hundred day moving average price of $174.31.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The business had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. Zoetis’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.41 earnings per share. Equities analysts predict that Zoetis Inc. will post 5.84 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ZTS shares. Piper Sandler raised their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Stifel Nicolaus increased their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, BTIG Research raised their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $218.22.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.